LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Rapid and Inexpensive Paper-Based Test Simultaneously Quantifies Multiple Cardiac Biomarkers

By LabMedica International staff writers
Posted on 02 May 2023
Print article
Image: Deep learning-enabled multiplexed POC sensor using paper-based fluorescence vertical flow assay (Photo courtesy of UCLA)
Image: Deep learning-enabled multiplexed POC sensor using paper-based fluorescence vertical flow assay (Photo courtesy of UCLA)

Centralized lab testing has long been the go-to method for diagnosing common illnesses. However, this approach often necessitates costly medical equipment and complex procedures that can only be carried out by highly trained professionals within a medical facility. These factors prolong testing time and hinder the widespread application of diagnostics in remote and resource-poor areas due to limited access to central labs. In response to these challenges, point-of-care (POC) sensors were developed as alternative diagnostic tools, characterized by their simplicity, rapid operation, compact size, and affordability. The most prevalent type of POC tests are paper-based sensors, also known as lateral flow assays (LFAs), where the injected sample fluid flows horizontally and reacts with specific test regions (test lines) to generate, for instance, a color change. Despite their ease of use and cost-effectiveness, existing LFAs have certain drawbacks, such as lower sensitivity and challenges with multiplexed testing for disease biomarkers.

To address these shortcomings, researchers at University of California (UCLA, Los Angeles, CA, USA) have devised a novel paper-based biosensor that utilizes a fluorescent multiplexed vertical flow assay to rapidly and simultaneously measure three cardiac biomarkers from human serum samples. This new paper-based POC sensor's vertical flow design allows for multiple test regions with up to 100 individual test spots on a single disposable cartridge. The powerful sensor operates with just a small serum droplet and can be easily used by a minimally trained individual in under 15 minutes per patient. Along with its multiplexing capabilities, the paper-based sensor also boasts high sensitivity, achieving a detection limit better than ~0.5 ng/mL for each biomarker — less than one billionth of half a gram per milliliter of serum.

Additionally, the UCLA researchers have created a mobile phone-based, low-cost handheld fluorescence reader and a deep learning-assisted signal analysis pipeline to automatically and accurately quantify the three target biomarkers in a user-friendly manner. The team tested their paper-based multiplexed sensor for the quantification of three biomarkers of acute coronary syndrome (ACS), including myoglobin, creatine kinase-MB (CK-MB), and heart-type fatty acid binding protein (FABP). ACS is a cardiovascular condition that demands prompt diagnosis in emergency situations, and these target markers are released into the bloodstream shortly after symptom onset. The newly-developed paper-based sensor was evaluated on human serum samples, and the measured concentrations for all three cardiac biomarkers aligned well with the benchmark measurements obtained by a standard laboratory test. Given its accuracy, speed, user-friendliness, and affordability, this deep learning-enabled paper-based multiplexed sensor offers an attractive POC testing option for various applications in remote and resource-limited settings.

“Compared to a commonly used linear calibration method, our deep learning-based analysis benefits from the function approximation power of neural networks to learn non-trivial relationships between the multiplexed fluorescence signals from the paper-based sensor and the underlying analyte concentrations in serum,” said Artem Goncharov, a graduate student at UCLA Electrical & Computer Engineering Department. “As a result, we have accurate quantitative measurements for all three biomarkers of interest despite the background noise present in clinical serum samples.”

Related Links:
UCLA 

Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Fecal DNA Extraction Kit
QIAamp PowerFecal Pro DNA Kit
New
High Performance Centrifuge
CO336/336R

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.